Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy | MicrobiomeTrials← Back to trialsNCT06586281
Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2025-06-01Est. Completion: 2027-09-01
Enrollment target: 20 participants Locations- University of California, San Diego, San Diego, California, United States
Other microbiome trials you might be interested in
Atopic Dermatitis (Eczema)Psoriasis
The goal of this clinical trial is to demonstrate the feasibility of a trial that examines the impact of changes in diet…
San Francisco, United StatesEst. completion Mar 17, 2028
Polymyalgia RheumaticaInflammatory Rheumatism
Pseudo-rheumatoid arthritis (PRA) is a common inflammatory rheumatic disease of the elderly, characterized by inflammato…
Rouen, FranceEst. completion Jul 1, 2031